Ignite Creation Date:
2024-05-06 @ 9:19 AM
Last Modification Date:
2024-10-26 @ 12:13 PM
Study NCT ID:
NCT02957019
Status:
TERMINATED
Last Update Posted:
2023-10-10
First Post:
2016-10-27
Brief Title:
A Phase III Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma DLBCL
Sponsor:
Organization:
Philogen SpA